Full metadata record
DC FieldValueLanguage
dc.creatorEstella-Hermoso-de-Mendoza, A. (Ander)-
dc.creatorCampanero, M.A. (Miguel Angel)-
dc.creatorLana, H. (Hugo)-
dc.creatorVilla-Pulgarin, J.A. (Janny A.)-
dc.creatorIglesia-Vicente, J. (Janis) de la-
dc.creatorMollinedo, F. (Faustino)-
dc.creatorBlanco-Prieto, M.J. (María José)-
dc.date.accessioned2013-05-06T14:11:12Z-
dc.date.available2013-05-06T14:11:12Z-
dc.date.issued2012-
dc.identifier.citationAnder Estella-Hermoso de Mendoza, Miguel A Campanero, Hugo Lana, Janny A Villa-Pulgarin, Janis de la Iglesia-Vicente, Faustino Mollinedo, and María J Blanco-Prieto. Complete inhibition of extranodal dissemination of lymphoma by edelfosine-loaded lipid nanoparticles. Nanomedicine, May 2012, Vol. 7, No. 5 , Pages 679-690es_ES
dc.identifier.issn1743-5889-
dc.identifier.urihttp://hdl.handle.net/10171/29159-
dc.description.abstractLipid nanoparticles (LN) made of synthetic lipids Compritol® 888 ATO and Precirol® ATO 5 were developed, presenting an average size of 110.4 ± 2.1 nm and 103.1 ± 2.9 nm, for Compritol® and Precirol®, respectively, and encapsulation efficiency above 85 % for both type of lipids. These LN decrease the hemolytic toxicity of the drug by 90 %. Pharmacokinetic and biodistribution profiles of the drug were studied after intravenous and oral administration of edelfosine-containing LN, providing an increase in relative oral bioavailability of 1500 % after a single oral administration of drug-loaded LN, maintaining edelfosine plasma levels over 7 days in contrast to a single oral administration of edelfosine solution, which presents a relative oral bioavailability of 10 %. Moreover, edelfosine-loaded LN showed a high accumulation of the drug in lymph nodes and resulted in slower tumor growth than the free drug in a murine lymphoma xenograft model, as well as potent extranodal dissemination inhibition.es_ES
dc.language.isoenges_ES
dc.publisherFuture Medicinees_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectEdelfosinees_ES
dc.subjectLipid nanoparticleses_ES
dc.subjectBioavailabilityes_ES
dc.subjectPharmacokineticses_ES
dc.subjectBiodistributiones_ES
dc.subjectLymphomaes_ES
dc.titleComplete inhibition of extranodal dissemination of lymphoma by edelfosine-loaded lipid nanoparticleses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttp://dx.doi.org/10.2217/nnm.11.134es_ES
dc.type.driverinfo:eu-repo/semantics/articlees_ES

Files in This Item:
File: 
Estella et al_Manuscript_Nanomedicine.pdf
Description: 
Size: 
1,37 MB
Format: 
Adobe PDF
File: 
Figure 1.pdf
Description: 
Size: 
158,21 kB
Format: 
Adobe PDF
File: 
Figure 2.pdf
Description: 
Size: 
199,98 kB
Format: 
Adobe PDF
File: 
Figure 3.pdf
Description: 
Size: 
44,29 kB
Format: 
Adobe PDF
File: 
Figure 4.pdf
Description: 
Size: 
199,86 kB
Format: 
Adobe PDF
File: 
Figure 5.pdf
Description: 
Size: 
78,38 kB
Format: 
Adobe PDF
File: 
Figure 6.pdf
Description: 
Size: 
54,33 kB
Format: 
Adobe PDF
File: 
Tables.pdf
Description: 
Size: 
196,45 kB
Format: 
Adobe PDF
File: 
Estella et al- Figure Legends_Revised.pdf
Description: 
Size: 
27,09 kB
Format: 
Adobe PDF


Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.